Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesday that clinical results from its Phase 1/2 study of JBI-802, a first-in-class, orally administered dual inhibitor of LSD1 and HDAC6 (CoREST), have been selected for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place 12-15 December 2026, in New Orleans and online.

The oral presentation will include results from the Phase 1 portion of the study, an open-label, multicentre trial designed to evaluate the safety, tolerability and preliminary efficacy of JBI-802. The study has enrolled patients with essential thrombocythemia (ET), polycythaemia vera (PV) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) with thrombocytosis who were relapsed, refractory or intolerant to standard of care (JBI-802-02; ACTRN12624000478516).

JBI-802 is an orally administered dual inhibitor of lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6) that targets the CoREST complex. The company says that it is designed to act on multiple disease-relevant processes, including abnormal megakaryocyte differentiation, platelet production, leukocyte proliferation and inflammatory signaling. JBI-802 is being evaluated in an ongoing Phase 1/2 study in patients with ET and other thrombocytosis-predominant myeloid malignancies (JBI-802-02; ACTRN12624000478516; NCT07612280).